Join Hansa Biopharma for a Capital Markets Day featuring key opinion leaders: Matthew Cooper, MD (Medical College of Wisconsin), Nassim Kamar, MD, PhD (Toulouse University Hospital, France), Roslyn Mannon, MD (University of Nebraska Medical Center), and Annette Jackson, PhD, F(ACHI) (Duke University Medical Center), and presentations by management on the Company’s pre-launch activities and pipeline strategy.

The program will include a review of the results from the pivotal U.S. Phase 3 ConfIdeS study presented at ATC on June 20-24, 2026, as well as findings from the European Post‑Authorisation Efficacy and Safety (PAES) study with Idefirix/imlifidase in Europe. Discussions with KOLs will focus on the medical need in the context of existing alternatives today for highly sensitized patients, as well as experiences from the Phase 3 study. Company presentations will address the market opportunity and Hansa Biopharma’s pre-launch and commercialization preparations ahead of a potential U.S. approval. The day will also feature an update on Hansa’s development program for the next generation enzyme HNSA-5487 in Guillain-Barré syndrome.

A live question and answer session will follow the formal presentations.